American Association of Individual Investors

Which Is a Better Investment, Halozyme Therapeutics, Inc. or Zymeworks Inc. Stock?

Learn more about whether Halozyme Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
BMJ Case Reports

Extracorporeal membrane oxygenation for pulmonary haemorrhage

Extracorporeal membrane oxygenation (ECMO) technology has relative contraindications in haemorrhagic disease but remains an effective therapeutic option for the treatment of pulmonary haemorrhage ...

FDA approves first subcutaneous drug for EGFR-mutated non-small cell lung cancer

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The American Journal of Managed Care

Intravenous vs Subcutaneous Oncology Therapies: Balancing Efficacy, Efficiency, and Patient Experience

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...
The American Journal of Managed Care

FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC

The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...

Journey to the center of a quantized vortex: How microscopic mutual friction governs superfluid dissipation

Step inside the strange world of a superfluid, a liquid that can flow endlessly without friction, defying the common-sense ...
eLife

PRRT2 as an auxiliary regulator of Nav channel slow inactivation

This important study identifies PRRT2 as an auxiliary regulator of Nav channel slow inactivation, proposing that PRRT2 facilitates entry into, and delays recovery from, the slow-inactivated state. The ...